News & Articles 09/11/2023 Our Network AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Global rights to Eccogene’s next-generation oral glucagon-like peptide 1 receptor agonist, ECC5004 as monotherapy and combination therapies.
